Result card

  • ORG1: How does IGG affect the current work processes?
English

How does IGG affect the current work processes?

Authors: Pseudo117 Pseudo117, Pseudo451 Pseudo451, Pseudo136 Pseudo136, Pseudo262 Pseudo262

Internal reviewers: Pseudo291 Pseudo291, Pseudo340 Pseudo340

Currently, IVIG is not an approved as a treatment option in Mild Cognitive Impairment and Alzheimer’s disease (AD), therefore there are no relevant clinical guidelines on its position in the treatment pathway (for example whether it would replace existing pharmacological and other interventions or constitute an add-on therapy).

In terms of its impact on the patient pathway, with regard to AD, IVIG has a different route of administration compared to pharmacological treatments used in the management of AD. In specific, administration of IVIG for its approved indications is mainly done in the hospital setting or in infusion clinics ({White-Reid K, 2008}{1}, although depending on the clinical characteristics of the patients, alternative site of care (GP office, home care) can be used.

Taking into consideration recommendations on IVIG use for its licensed indications, patients may also need to undergo pre-treatment testing and routine monitoring for development of complications after treatment with IVIG {Silvergleid and Berger} {2}. Finally, delayed disease progression would affect AD prevalence and consequently impact the service delivery models {Brodaty el al}{ {3}.

Refer to TEC 4, TEC 5, TEC8.

Critical
Partially
Pseudo117 P et al. Result Card ORG1 In: Pseudo117 P et al. Organisational aspects In: Jefferson T, Cerbo M, Vicari N [eds.]. Use of Intravenous immunoglobulins for Alzeheimer’s disease including Mild Cognitive Impairment [Core HTA], Agenas - Agenzia nazionale per i servizi sanitari regionali ; 2015. [cited 30 October 2020]. Available from: http://corehta.info/ViewCover.aspx?id=267

References